Incyte Corporation (INCY) Stock Price Today
Aura AI Summary
Key Stats
- $23.44BMarket Cap
- -Volume
- HealthSector
- $118.5252W High
- $68.9052W Low
- -Typical Hold Time
- $19.46BEnterprise Value
- -Div Yield
- -Trading Activity
Track Incyte Corporation (INCY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Incyte Corporation has traded between a low of $68.9 and a high of $118.52, highlighting its annual price range. Buy and sell Incyte Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Most Recent News
Global Botulinum Toxin in Urology Market to reach $1.98B by 2035 with 6.08% CAGR, driven by aging population and advanced treatments
The global Botulinum Toxin in Urology Market is projected to grow from approximately USD 1.16 billion in 2026 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is fueled by increasing prevalence of urological disorders like overactive bladder, ...
BioLife Solutions downgraded to Hold amid $1.5B Repligen acquisition and shareholder fairness probe
BioLife Solutions stock was downgraded to a 'Hold' rating with a $31 price target by Lake Street amid its proposed $1.5 billion acquisition by Repligen Corporation. The deal, a cash-and-stock offer, is under legal scrutiny by Halper Sadeh LLC, which ...
Robotic endoscopy devices market to grow at 10% CAGR, reaching $6.5B by 2034 driven by tech advances and rising GI disorders.
The global robotic endoscopy devices market is projected to grow at a compound annual growth rate (CAGR) of about 10% from 2026 to 2034, reaching an estimated value of $6.5 billion by 2034. This growth is fueled by increasing demand for minimally inv...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.